Quantitative immunocytochemical assays on frozen sections of p53: Correlation to the follow-up of patients with breast carcinomas

American Journal of Clinical Pathology

Volumn 106, Issue 5, 1996, Pages 640-646

  Charpin, Colette ^a,c   Garcia, Stéphane ^a   Bouvier, Corinne ^a   Andrac, Lucile ^a   Devictor, Benedicte ^a   Lavaut, Marie Noëlle ^a   Allasia, C ^a   Bonnier, Pascal ^b   Piana, Lucien ^b  

^a HÔPITAL NORD   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Breast carcinomas; Frozen sections; p53; Patient's outcome; Quantitative immunocytochemistry

Indexed keywords

BIOTIN; PROTEIN P53; STREPTAVIDIN;

ARTICLE; BREAST CARCINOMA; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FROZEN SECTION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS;

EID: 0029842965     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/106.5.640     Document Type: Article

References (41)

1. Harris CC, Hollstein M. Clinical implications of the p53 tumorsuppressor gene. N Engl J Med 1993;329:1318-1327.
2. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Sciences 1991;253:49-53.
3. Mazard R, Spinardi L, Ben Cheikh M, et al. p53 mutations occur in aggressive breast cancer. Cancer Res 1992;52:3918-3923.
4. Miller C, Mohandas T, Wolf D, et al. Human p53 gene localized to short arm of chromosome 17. Nature 1986;319:783-784.
5. Blaszyk H, Vaughn CB, Hartmann A, et al. Novel pattern of p53 gene mutations in an American black cohort with high mortality from breast cancer. Lancet 1994;343:1195-1197.
6. Andersen TI, Holm R, Nesland JM, et al. Prognostic significance of Tp53 alterations in breast carcinoma. Br J Cancer 1993;68:540-548.
7. Faille A, De Cremoux P, Extra JM, et al. p53 mutations and over-expression in locally advanced breast cancers. Br J Cancer 1994;69:1145-1150.
8. Marchetti A, Buttitta F, Pellegrini S, et al. p53 mutations and histological type of invasive breast carcinoma. Cancer Res 1993;53:4665-4669.
9. Elledge RM, Fuqua ASW, Clark GM, et al. Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat 1993;26:225-235.
10. Silvestrini R, Veneroni S, Daidone MG, et al. The bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994;86:499-504.
11. Haldar S, Negrini M, Monne M, et al. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994;54:2095-2097.
12. Eliyahu D, Raz A, Gruss P, et al. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature 1984;312:646-649.
13. Chin KV, Ueda K, Pastan I, et al. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992;255:459-462.
14. Nguyen KT, Liu B, Ueda K, et al. Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants. Oncol Res 1994;6:71-77.
15. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-546.
16. Charpin C, Devictor B, Andrac L, et al. p53 quantitative immunocytochemical assays in breast carcinomas. Hum Pathol 1995;26:159-166.
17. Hurlimann J, Chaubert P, Benhattar J. p53 gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: Correlation between immunohistochemical and molecular biology techniques. Mod Pathol 1994;7:423-427.
18. Bhargava V, Thor A, Deng G, et al. The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer. Mod Pathol 1994;7:361-368.
19. Tsuda H, Hirohashi S. Association among p53 gene mutation nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer. Int J Cancer 1994;57:498-503.
20. Jacquemier J, Moles JP, Penault-Llorca F, et al. p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer 1994;69:846-852.
21. O'Malley FP, Vnencak-Jones CL, Dupont WD, et al. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast: Immunohistochemical and sequencing data. Lab Invest 1994;71:67-72.
22. Hall PA, Lane DP. p53 in tumour pathology: Can we trust immunohistochemistry? J Pathol 1994;172:1-4.
23. Allred DC, Clark GM, Alledge R, et al: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200-206.
24. Sawan A, Randall B, Angus R, et al. Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: An immunohistochemical study. J Pathol 1992;168:23-28.
25. Barnes DM, Dublin EA, Fisher CJ, et al. Immunohistochemical detection of p53 protein in mammary carcinoma: An important new independent indicator of prognosis? Hum Pathol 1993;24: 469-476.
26. Visscher DW, Sarkar FH, Wykes S, et al. Clinicopathologic significance of p53 immunostaining in adenocarcinoma of the breast. Arch Pathol Lab Med 1993;117:973-976.
27. Marks JR, Humphrey PA, Wu K, et al. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 1994;219:332-341.
28. Lipponen P, Aaltomaa S, Syrjänen S, et al. p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer 1993;55:51-56.
29. Thor AD, Moore DH, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-855.
30. Cunningham JM, Ingle JN, Jung SH, et al. p53 gene expression in node-positive breast cancer: Relationship to DNA ploidy and prognosis. J Natl Cancer Inst 1994;86:1871-1873.
31. McGuire WL. Adjuvant therapy of node-negative breast cancer. N Engl J Med 1989;320:525-527.
32. Caleffi M, Teague MW, Jensen RA, et al. p53 gene mutations and steroid receptor status in breast cancer. Cancer 1994;73:2147-2156.
33. Schneider J, Rubio MP, Rodriguez-Escudero FJ, et al. Identification of p53 mutations by means of single strand conformation polymorphism analysis in gynaecological tumours : comparison with the results of immunohistochemistry. Eur J Cancer 1994;30A:504-508.
34. Fisher CJ, Gillett CE, Vojtesek B, et al. Problems with p53 immunohistochemical staining: The effect of fixation and variation in the methods of evaluation. Br J Cancer 1994;69:26-31.
35. Bloom HJG. Prognosis in carcinoma of the breast. Br J Cancer 1950;4:259-288.
36. Maudelonde T, Brouillet JP, Roger P, et al. Immunostaining of cathepsin D in breast cancer: Quantification by computerized image analysis and correlation with cytosolic assay. Eur J Cancer 1992;28:1686-1691.
37. Altman DG, Lausen B, Sauerberi W, Schumacher M. Dangers of using "optimal" cutpoint in the evaluation of prognostic factors. J Nat Cancer Inst 1994;86:829-835.
38. Charpin C, Andrac L, Vacheret H, et al. Multiparametric evaluation (SAMBA) of growth fraction (monoclonal Ki67) in breast carcinoma tissue sections. Cancer Res 1988;48:4368-4374.
39. Charpin C, Devictor B, Bonnier P, et al. Expression of HER-2/neu oncogene in breast cancer Correlation of quantitative immunocytochemistry and prognostic factors. Int J Oncol 1992;1:815-823.
40. Charpin C, Devictor B, Bonnier P, et al. Cathepsin D immunocytochemical assays in breast carcinomas: Image analysis and correlation to prognostic factors. J Pathol 1993;170:463-470.
41. Charpin C, Devictor B, Bergeret D, et al. CD31 quantitative immunocytochemical assays in breast carcinomas: Correlation with current prognostic factors. Am J Clin Pathol 1995;103:443-448.